Oncotarget

Research Papers:

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells

Luigi Ippolito, Alberto Marini, Lorenzo Cavallini, Andrea Morandi, Laura Pietrovito, Gianfranco Pintus, Elisa Giannoni, Thomas Schrader, Martin Puhr, Paola Chiarugi and Maria Letizia Taddei _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:61890-61904. https://doi.org/10.18632/oncotarget.11301

Metrics: PDF 3948 views  |   HTML 5475 views  |   ?  


Abstract

Luigi Ippolito1, Alberto Marini5, Lorenzo Cavallini1, Andrea Morandi1, Laura Pietrovito1, Gianfranco Pintus5,6, Elisa Giannoni1, Thomas Schrader2, Martin Puhr3, Paola Chiarugi1,4,*, Maria Letizia Taddei7,*

1Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

2Department of Chemistry, University Duisburg-Essen, Essen, Germany

3Department of Urology, Medical University of Innsbruck, Innsbruck, Austria

4Tuscany Tumor Institute and “Center for Research, Transfer and High Education DenoTHE”, Florence, Italy

5Department of Biomedical Sciences, Laboratory of Cell Signaling and Redox Biology, University of Sassari, Sassari, Italy

6Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar

7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

*These authors have contributed equally to this work

Correspondence to:

Maria Letizia Taddei, email: [email protected]

Keywords: prostate cancer, chemoresistance, docetaxel, oxidative phosphorylation, epithelial mesenchymal transition

Received: March 30, 2016    Accepted: July 27, 2016    Published: August 16, 2016

ABSTRACT

Drug resistance of cancer cells is recognized as the primary cause of failure of chemotherapeutic treatment in most human cancers. Growing evidences support the idea that deregulated cellular metabolism is linked to such resistance. Indeed, both components of the glycolytic and mitochondrial pathways are involved in altered metabolism linked to chemoresistance of several cancers. Here we investigated the drug-induced metabolic adaptations able to confer advantages to docetaxel resistant prostate cancer (PCa) cells. We found that docetaxel-resistant PC3 cells (PC3-DR) acquire a pro-invasive behavior undergoing epithelial-to-mesenchymal-transition (EMT) and a decrease of both intracellular ROS and cell growth. Metabolic analyses revealed that PC3-DR cells have a more efficient respiratory phenotype than sensitive cells, involving utilization of glucose, glutamine and lactate by the mitochondrial oxidative phosphorylation (OXPHOS). Consequently, targeting mitochondrial complex I by metformin administration, impairs proliferation and invasiveness of PC3-DR cells without effects on parental cells. Furthermore, stromal fibroblasts, which cause a “reverse Warburg” phenotype in PCa cells, reduce docetaxel toxicity in both sensitive and resistant PCa cells. However, re-expression of miR-205, a microRNA strongly down-regulated in EMT and associated to docetaxel resistance, is able to shift OXPHOS to a Warburg metabolism, thereby resulting in an elevated docetaxel toxicity in PCa cells. Taken together, these findings suggest that resistance to docetaxel induces a shift from Warburg to OXPHOS, mandatory for conferring a survival advantage to resistant cells, suggesting that impairing such metabolic reprogramming could be a successful therapeutic approach.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11301